FIBROGEN INC - COMMON

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

13 نوفمبر 2024 15:58:52 بحسب NetDania Notify

FibroGen Reports Third Quarter 2024 Financial Results

12 نوفمبر 2024 16:05:02 بحسب Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2024 Financial Results

04 نوفمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

31 أكتوبر 2024 16:00:39 بحسب NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

28 أكتوبر 2024 10:16:28 بحسب NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

09 أكتوبر 2024 10:58:40 بحسب NetDania Notify

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

08 أكتوبر 2024 09:46:54 بحسب NetDania Notify

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 سبتمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months Low: FIBROGEN INC - COMMON STOCK

03 سبتمبر 2024 12:45:29 بحسب NetDania Notify

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

06 أغسطس 2024 16:05:02 بحسب Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2024 Financial Results

30 يوليو 2024 16:07:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

30 يوليو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

18 يونيو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

03 يونيو 2024 16:05:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

03 يونيو 2024 16:02:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

23 مايو 2024 17:05:00 بحسب Nasdaq GlobeNewswire

FibroGen to Participate in Upcoming Investor Conferences

07 مايو 2024 07:00:01 بحسب Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2024 Financial Results

06 مايو 2024 16:02:00 بحسب Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2024 Financial Results

29 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

24 أبريل 2024 16:02:00 بحسب Nasdaq GlobeNewswire